DDIT3 and diffuse large B-cell lymphoma: Meanwhile, DLBCL is remediable in more than 60% patients when treated with standard treatment, known as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)4, so it is important to seek out optimal biomarkers which could identify the rest of patients who failed to be cured with R-CHOP treatment.